Comparing Tegoprazan and Pantoprazole for Treating Gastroesophageal Reflux Disease in Adults

What this Trial Is About

Researchers are comparing two drugs, tegoprazan and pantoprazole, to see which one better resolves symptoms in adult patients diagnosed with erosive and non-erosive gastroesophageal reflux disease GERD. The study aims to determine the proportion of patients whose main GERD symptoms improve after four weeks of treatment. This phase 4 clinical trial is sponsored by Carnot Laboratories and uses a randomized, double-blind design to ensure unbiased results. Participants are assigned to one of four groups based on their GERD type non-erosive or erosive. Each group receives either tegoprazan 50 mg or pantoprazole 40 mg, both taken daily for 28 days. This setup allows the study to compare the effectiveness of these two acid-suppressing medications in managing GERD symptoms. During the trial, researchers will monitor symptom resolution from enrollment through the end of the four-week treatment. Participants undergo diagnostic tests such as endoscopy and impedance pHmetry before joining to confirm GERD. The study tracks symptom improvements and safety throughout the treatment period, with the main outcome being the proportion of subjects who experience symptom resolution after four weeks.

Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole